LS-P-Tropion-02

A Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigators Choice in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Metastatic Triple-negative Breast Cancer